Alto Neuroscience(ANRO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ANRO Alto Neuroscience

Market Closed 12-12 16:00:00 EST

15.13

+0.45

+3.07%

盘后15.34

+0.21+1.39%

19:42 EST

High15.23	Low14.40	Vol217.79K
Open14.96	D1 Closing14.68	Amplitude5.65%
Mkt Cap470.03M	Tradable Cap363.02M	Total Shares31.07M
T/O3.25M	T/O Rate0.91%	Tradable Shares23.99M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ANRO","market":"US","secType":"STK","nameCN":"Alto Neuroscience","latestPrice":15.13,"timestamp":1765573200000,"preClose":14.68,"halted":0,"volume":217787,"hourTrading":{"tag":"盘后","latestPrice":15.34,"preClose":15.13,"latestTime":"19:42 EST","volume":1193,"amount":18081.28,"timestamp":1765586550970},"delay":0,"floatShares":23993387,"shares":31066335,"eps":-2.305836,"marketStatus":"Market Closed","change":0.45,"latestTime":"12-12 16:00:00 EST","open":14.96,"high":15.23,"low":14.4,"amount":3252436.284888,"amplitude":0.05654,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.305836,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1706850000000,"exchange":"NYSE","adjPreClose":14.68,"preHourTrading":{"tag":"盘前","latestPrice":14.69,"preClose":14.68,"latestTime":"09:16 EST","volume":41,"amount":602.310008,"timestamp":1765549012359},"postHourTrading":{"tag":"盘后","latestPrice":15.34,"preClose":15.13,"latestTime":"19:42 EST","volume":1193,"amount":18081.28,"timestamp":1765586550970},"volumeRatio":0.7564270619545327,"impliedVol":0.8637,"impliedVolPercentile":0.236},"requestUrl":"/m/hq/s/ANRO/tweets","defaultTab":"tweets","newsList":[{"id":"2588502125","title":"Alto Neuroscience Grants New Employee Stock Option Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2588502125","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588502125?lang=en_us&edition=fundamental","pubTime":"2025-12-04 05:05","pubTimestamp":1764795925,"startTime":"0","endTime":"0","summary":"Alto Neuroscience Inc. has granted a new employee an option to purchase 150,000 shares of its common stock at an exercise price of $12.80 per share, the closing price on the date of the grant. The stock option has a 10-year term and will vest over four years, with 25% vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal monthly installments over the following 36 months, contingent on the employee's continued service with the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief via Business Wire  on December 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL8WgrM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2586786289","title":"Alto Neuroscience Inc Files for Proposed Resale of up to 8.5 Mln Shares by Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2586786289","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586786289?lang=en_us&edition=fundamental","pubTime":"2025-11-28 19:02","pubTimestamp":1764327752,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nFWN3X40EG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2584625079","title":"This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2584625079","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584625079?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:14","pubTimestamp":1763385240,"startTime":"0","endTime":"0","summary":"Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/17/Analyst-Works-On-Personal-Computer-Showi.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/17/Analyst-Works-On-Personal-Computer-Showi.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/initiation/25/11/48896140/this-alto-neuroscience-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-monday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/initiation/25/11/48896140/this-alto-neuroscience-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["ANRO","BK4007","BK4112"],"gpt_icon":0},{"id":"2584640608","title":"Alto Neuroscience Inc : Btig Initiates Coverage With Buy Rating; Target Price $27","url":"https://stock-news.laohu8.com/highlight/detail?id=2584640608","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584640608?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:57","pubTimestamp":1763380636,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nFWN3WT1JL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2584644000","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2584644000","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584644000?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:00","pubTimestamp":1763377200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·J & J Snack Fds                                 4Q      1.24        BMO","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLCO","CPRT","TGT","ACM","CING","DLB","WB","BZ","BULL","AREC","BBWI","CGON","ARMK","ATRA","WMT","NVDA","CRGO","ADIL","BV","DY","CRDL","BRBR","ARBE","CRNC","ALLT","ATKR","TCOM","POWL","ANRO","CLSD","AZTA","BNTC","NTES","XP","AS","ATOS","CPA","ZTO","ENTA","VIPS","DE","EARN","ENR","BMA","TBBB","CDLR","AHL"],"gpt_icon":1},{"id":"2584642559","title":"Alto Neuroscience Initiated at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2584642559","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584642559?lang=en_us&edition=fundamental","pubTime":"2025-11-17 18:59","pubTimestamp":1763377140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANRO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 17, 2025 05:59 ET (10:59 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2584644771","title":"Alto Neuroscience initiated with a Buy at BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2584644771","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584644771?lang=en_us&edition=fundamental","pubTime":"2025-11-17 18:55","pubTimestamp":1763376904,"startTime":"0","endTime":"0","summary":"BTIG analyst Thomas Shrader initiated coverage of Alto Neuroscience (ANRO) with a Buy rating and $27 price target The company is focused on next-ge...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alto-neuroscience-initiated-with-a-buy-at-btig-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alto-neuroscience-initiated-with-a-buy-at-btig-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2584690224","title":"Stifel Nicolaus Keeps Their Buy Rating on Alto Neuroscience, Inc. (ANRO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584690224","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584690224?lang=en_us&edition=fundamental","pubTime":"2025-11-17 10:05","pubTimestamp":1763345117,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Alto Neuroscience, Inc. on November 14 and set a price target of $33.00. The compan...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-alto-neuroscience-inc-anro-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-alto-neuroscience-inc-anro-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANRO","SF"],"gpt_icon":0},{"id":"2583068338","title":"Alto Neuroscience, Inc.: Promising Future with Strategic Advancements and Strong Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2583068338","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583068338?lang=en_us&edition=fundamental","pubTime":"2025-11-15 00:45","pubTimestamp":1763138736,"startTime":"0","endTime":"0","summary":"Alto Neuroscience, Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C. Wainwright...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/alto-neuroscience-inc-promising-future-with-strategic-advancements-and-strong-financial-position-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/alto-neuroscience-inc-promising-future-with-strategic-advancements-and-strong-financial-position-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","XLV","LABU","BK4585","ANRO","BK4588","XBI","BK4581"],"gpt_icon":0},{"id":"2583980577","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2583980577","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583980577?lang=en_us&edition=fundamental","pubTime":"2025-11-14 19:00","pubTimestamp":1763118000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Li Auto Inc. Sp ADR                               3Q       .10. ·J & J Snack Fds                                 4Q      1.24        BMO","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADIL","ATRA","AZTA","CRNC","ANRO","ALLT","BNZI","CLCO","TGT","ARMK","DEFT","BRBR","CRGO","DY","ATOS","CDLR","ACM","BMA","ATKR","CGON","ATAI","NVDA","BBAR","DE","TCOM","NTES","AS","BZ","BV","DLB","WB","AREC","CING","CRDL","LGN","ARBE","BNTC","POWL","BTBT","CPA","BBWI","AHL","CLSD","XP","ZTO"],"gpt_icon":1},{"id":"2583626589","title":"Promising Future for Alto Neuroscience: Buy Rating Backed by Strong Financials and Clinical Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2583626589","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583626589?lang=en_us&edition=fundamental","pubTime":"2025-11-13 06:05","pubTimestamp":1762985121,"startTime":"0","endTime":"0","summary":"William Blair analyst Myles Minter has reiterated their bullish stance on ANRO stock, giving a Buy rating today. Myles Minter has given his Buy rat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-future-for-alto-neuroscience-buy-rating-backed-by-strong-financials-and-clinical-advancements-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-future-for-alto-neuroscience-buy-rating-backed-by-strong-financials-and-clinical-advancements-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANRO"],"gpt_icon":0},{"id":"2583651583","title":"Alto Neuroscience’s ALTO-207: A Promising Candidate for Treatment-Resistant Depression with Significant Financial Projections","url":"https://stock-news.laohu8.com/highlight/detail?id=2583651583","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583651583?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:05","pubTimestamp":1762981541,"startTime":"0","endTime":"0","summary":"Alto Neuroscience, Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Justin Walsh from JonesTrading reiter...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/alto-neurosciences-alto-207-a-promising-candidate-for-treatment-resistant-depression-with-significant-financial-projections-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/alto-neurosciences-alto-207-a-promising-candidate-for-treatment-resistant-depression-with-significant-financial-projections-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","XBI","BK4109","BK4585","ANRO","BK4588","XLV","BK4138","BK4581","ALTO","BK4007"],"gpt_icon":0},{"id":"2583024593","title":"Alto Neuroscience Is Maintained at Buy by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2583024593","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583024593?lang=en_us&edition=fundamental","pubTime":"2025-11-13 03:47","pubTimestamp":1762976820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANRO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 12, 2025 14:47 ET (19:47 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO"],"gpt_icon":0},{"id":"2583630348","title":"Wedbush Adjusts Alto Neuroscience Price Target to $13 From $12, Maintains Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2583630348","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583630348?lang=en_us&edition=fundamental","pubTime":"2025-11-13 00:01","pubTimestamp":1762963291,"startTime":"0","endTime":"0","summary":"Alto Neuroscience (ANRO) has an average rating of Buy and mean price target of $22.59, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ANRO"],"gpt_icon":0},{"id":"2583303482","title":"Alto Neuroscience price target raised to $25 from $15 at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2583303482","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583303482?lang=en_us&edition=fundamental","pubTime":"2025-11-12 23:45","pubTimestamp":1762962325,"startTime":"0","endTime":"0","summary":"Jefferies analyst Andrew Tsai raised the firm’s price target on Alto Neuroscience (ANRO) to $25 from $15 and keeps a Buy rating on the shares. Inve...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alto-neuroscience-price-target-raised-to-25-from-15-at-jefferies-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alto-neuroscience-price-target-raised-to-25-from-15-at-jefferies-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANRO"],"gpt_icon":0},{"id":"2582948374","title":"Alto Neuroscience Unveils Precision Medicine Strategy for Mental Health Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2582948374","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582948374?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:41","pubTimestamp":1762954866,"startTime":"0","endTime":"0","summary":"Alto Neuroscience Inc. has released a corporate presentation highlighting advancements in its clinical-stage precision medicine portfolio targeting central nervous system  disorders. The company is advancing multiple product candidates using a biomarker-driven approach to patient identification, aiming to improve clinical outcomes in mental health conditions such as depression, schizophrenia, and bipolar disorder. The presentation outlines ongoing and planned clinical trials, including Phase 2 and Phase 3 studies for several candidates such as ALTO-207, ALTO-300, ALTO-100, and ALTO-101, with upcoming data readouts expected over the next two years. Alto reports having dosed over 800 patients across its studies and maintains a cash runway to support further development. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely infor","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDLCXSyT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2582379678","title":"Alto Neuroscience Q3 EPS $(0.52) Beats $(0.67) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582379678","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582379678?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:58","pubTimestamp":1762952324,"startTime":"0","endTime":"0","summary":"Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.67) by 22.04 percent. This is a 16.13 percent increase over losses of $(0.62) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48800061/alto-neuroscience-q3-eps-0-52-beats-0-67-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO"],"gpt_icon":0},{"id":"2582653379","title":"Alto Neuroscience reports strong cash position and advances clinical trials for neuropsychiatric treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2582653379","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582653379?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:57","pubTimestamp":1762952263,"startTime":"0","endTime":"0","summary":"Alto Neuroscience Inc. reported a cash balance of $184.2 million as of October 31, 2025, following the closing of a $50 million PIPE financing. Research and development expenses for the quarter ended September 30, 2025, were $10.5 million, down from $13.1 million in the same period in 2024. General and administrative expenses were $4.4 million, compared to $5.8 million a year earlier. The company reported a net loss of $14.2 million for the quarter, compared to $16.8 million in the prior year. Alto expects its current cash position to fund operations into 2028 and support the advancement of its clinical pipeline, including the planned initiation of a Phase 2b trial for ALTO-207 in the first half of 2026 and a Phase 3 trial by early 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be inter","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL53dY8b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2582637963","title":"Alto Neuroscience Inc: Topline Data for Phase 2 Trials of Alto-101 in Cias Expected 1Q 2026 and Alto-300 in Mdd Expected Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2582637963","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582637963?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:57","pubTimestamp":1762952220,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUA2JKBDN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2582379909","title":"Alto Neuroscience : on Track to Initiate Phase 2B Trial in First Half of 2026 and Phase 3 Trial by Early 2027 for Alto-207","url":"https://stock-news.laohu8.com/highlight/detail?id=2582379909","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582379909?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:57","pubTimestamp":1762952220,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUA2JKBDN:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANRO","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.altoneuroscience.com","stockEarnings":[{"period":"1week","weight":0.1266},{"period":"1month","weight":0.0655},{"period":"3month","weight":2.8895},{"period":"6month","weight":5.278},{"period":"1year","weight":2.9504},{"period":"ytd","weight":2.5768}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD. In addition, the company develops novel pharmacodynamically synergistic combinations and an AI-enabled biomarker platform that combine sources of information on patients brain activity and behavior to identify patients to respond to novel product candidates. Alto Neuroscience, Inc. was incorporated in 2019 and is based in Los Altos, California.","exchange":"NYSE","name":"Alto Neuroscience","nameEN":"Alto Neuroscience"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alto Neuroscience(ANRO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alto Neuroscience(ANRO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alto Neuroscience,ANRO,Alto Neuroscience股票,Alto Neuroscience股票老虎,Alto Neuroscience股票老虎国际,Alto Neuroscience行情,Alto Neuroscience股票行情,Alto Neuroscience股价,Alto Neuroscience股市,Alto Neuroscience股票价格,Alto Neuroscience股票交易,Alto Neuroscience股票购买,Alto Neuroscience股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alto Neuroscience(ANRO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alto Neuroscience(ANRO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction